References

S
Schmidt AJ, Rockstroh JK, Vogel M, et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany--a case-control study. Jin X, ed. PLoS ONE. 2011;6(3):e17781.
Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing?. Antiviral Res. 2014;105:64-71.
Schoenbachler BT, Smith BD, Sena AC, et al. Hepatitis C virus testing and linkage to care in North Carolina and South Carolina jails, 2012-2014. Hilton A, Bachman S, Lunda M, Spaulding AC, eds. Public Health Rep. 2016;131(Suppl 2):98-104.
Schulkind J, Stephens B, Ahmad F, et al. High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. J Viral Hepat. 2019;26(5):519-528.
Schwarz KB, Rosenthal P, Murray KF, et al. Ledipasvir-sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C. Hepatology. 2019;DOI 10.1002/hep.30830 [Epub ahead of print]. doi:10.1002/hep.30830.
Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology. 2009;49(6):1821-1827.
Seem DL, Lee I, Umscheid CA, Kuehnert MJ. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep. 2013;128(4):247-343.
Seem DL, Lee I, Umscheid CA, Kuehnert MJ. Excerpt from PHS guideline for reducing HIV, HBV and HCV transmission through organ transplantation. Am J Transplant. 2013;13(8):1953-1962.
Selph S, Chou R. Impact of contacting study authors on systematic review conclusions: diagnostic tests for hepatic fibrosis. 2014;Rockville, MD: Agency for Healthcare Research and Quality.
Selvapatt N, Ward T, Bailey H, et al. Is antenatal screening for hepatitis C virus cost-effective? A decade's experience at a London centre. Bennett H, Thorne C, See L-M, et al., eds. J Hepatology. 2015;63(4):797-804.
Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2017. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0. Accessed Accessed June 13, 2019.
Shaw K, Gennat H, O'Rourke P, DelMar C. Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006;18(4):CD003817.
Shebl FM, El-Kamary SS, Saleh D'aA, et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. Abdel-Hamid M, Mikhail N, Allam A, et al., eds. J Med Virol. 2009;81(6):1024-1031.
Shelton BA, Sawinski D, Mehta S, Reed RD, MacLennan PA, Locke JE. Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney. Transpl Infect Dis. 2018;20:e12829.
Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139(6):493-498.
Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(6):683-694. doi:10.1093/cid/civ948.
Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):280-288, 288e1.
Sise ME, Goldberg DS, Schaubel DE, et al. One-year outcomes of the multi-center study to transplant hepatitis C-infected kidneys (MYTHIC) Trial. Kidney Int Rep. 2021;7(2):241-250. doi:10.1016/j.ekir.2021.11.022.
Sise ME, Chute DF, Oppong Y, et al. Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. Kidney Int. 2020;97(1):193-201. doi:10.1016/j.kint.2019.04.030.
Sise ME, Goldberg DS, Kort JJ, et al. Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol. 2020;31(11):2678-2687.
Top